INTRODUCTION {#s1}
============

Plasmablastic lymphoma (PBL) is a rare highly aggressive lymphoma that occurs most often in the context of Human Immunodeficiency Virus (HIV)-infection (40-50%), or in other settings of decreased immune surveillance \[[@R1]\]. Tumor cells have a well-defined morphology resembling B-immunoblasts, and express plasma cells markers \[[@R1]\]. However, a more or less pronounced plasmacytic differentiation as well as a variable expression of CD20 and PAX-5 can be encountered \[[@R2]\]. Therefore, the diagnosis of PBL is challenging because it has an overlap in cytomorphologic and immunophenotypic features with plasma cell neoplasms and with lymphomas that show blastic appearance (i.e. more immature, plasmablast-like morphology) \[[@R3]\]. Even using a comprehensive panel of immunostains, a confident differential diagnosis between PBL and anaplastic or plasmablastic extramedullary plasmacytoma (EMPC) is not always possible. Nonetheless, a proper distinction of these entities is mandatory as EMPC and PBL have different prognoses and currently benefit from different therapeutic strategies. On the other hand, the differential diagnosis between PBL and other lymphoma types with blastic appearance is often straightforward due to the lack of B-cell marker expression in PBL. However, BL shares numerous biologic similarities with PBL. In fact, the most frequently detected genomic alteration in PBL is t(8;14)(q24;q32) leading to *MYC/IGH* rearrangement observed in about 50% of cases \[[@R1], [@R3]\]. Other overlaps include cell morphology with the starry sky appearance, the high proliferation rate, the MYC protein over-expression and the association with EBV infection.

A common feature is the presence of the Epstein-Barr virus (EBV) DNA in tumor cells in 50 to 75% of cases, with higher frequency in HIV-positive cases \[[@R1], [@R3]\]. The molecular and genetic mechanisms underlying PBL pathogenesis remain largely unknown and are likely dependent on the complexity of biological interplays between immunodeficiency, molecular events (*MYC* gene rearrangements), co-infecting oncogenic viruses (EBV) \[[@R4]\] and chronic immune activation (expression of immune-checkpoint proteins) \[[@R5]\]. It is unknown, however, whether *MYC* translocation represents the initiating or a late genetic event in PBL pathogenesis, and furthermore the latency program of EBV in neoplastic cells is still debated. In fact, although the type I latency is commonly detected, type III latency can be observed in patients with HIV infection and in those patients with post-transplant PBL \[[@R3]\].

In the present study we aimed to better define the pathogenesis and molecular features of PBL by 1) assessing the EBV latency patterns in PBL by qPCR and immunohistochemistry; 2) performing, for the first time to the best of our knowledge, an unbiased miRNA profiling of PBL, EMPC, and BL by next generation sequencing (NGS).

RESULTS {#s2}
=======

qPCR and immunohistochemistry reveal a non-canonical latency type and an abortive lytic cycle of EBV in plasmablastic lymphoma {#s2_1}
------------------------------------------------------------------------------------------------------------------------------

We checked the expression of *EBNA-1, EBNA-2, EBNA-3, LMP-1, LMP-2A*, EBER transcripts, *BZLF-1/*ZEBRA, *BMRF-1*/Ea-D, *BHRF-1*/Ea-R, *BLLF1*/gp350 across the 13 PBL cases (12 EBV-positive and 1 EBV-negative). EBNA-1 was detected in 12/13 cases (92.3%), LMP-1 and LMP-2 in 1/13 and 10/13 (7.7% and 76.9%, respectively) (Figure [1](#F1){ref-type="fig"}), EBNA-2 and EBNA-3 in 0/13, and EBER in 12/13 (92.3%). *BZLF-1/*ZEBRA was found in 12/13 cases (92.3%) and both *BMRF-1*/Ea-D e *BHRF-1*/Ea-R in 10/13 (76.9%) (Figure [1](#F1){ref-type="fig"}), while none of the cases expressed BLLF1/gp350 (Figure [1](#F1){ref-type="fig"}).

![RT-qPCR and immunohistochemistry reveal a non-canonical latency type and an abortive lytic cycle of EBV in neoplastic cells\
*LMP-2A* **A.**, **E.**, *BZLF-1/*ZEBRA **B.**, **F.**, *BMRF-1*/Ea-D **C.**, **G.**, *BHRF-1*/Ea-R **D.**, **H.**, expression by RT-qPCR (across the 13 PBL cases) and immunohistochemistry (in one exemplificative PBL case; original magnification, 40x). In qPCR graphs, y-axis represents gene expression values (2 Delta Ct formula).](oncotarget-08-107356-g001){#F1}

We then determined the expression of all the corresponding encoded-proteins. Immunohistochemistry (IHC) confirmed the non-canonical latency associated program with the partial expression of some proteins characterizing latency II (i.e. LMP-1 in 1/13 and LMP-2 in 6/13 of the cases) (Figure [1](#F1){ref-type="fig"}). There was also the expression of proteins characterizing the lytic phase of the virus (i.e. BZLF-1/ZEBRA in 12/13, and BHRF-1/Ea-R and BMRF-1/Ea-D in 9/13 of the cases) (Figure [1](#F1){ref-type="fig"}). BLLF1/gp350 was not detected in any case. The qPCR data substantially corresponded to those obtained by IHC; however, slight differences emerged likely due to the higher sensitivity of qPCR.

The same analyses were then carried out in the validation cohort with substantially identical results (Figure [1](#F1){ref-type="fig"}; Table [3](#T3){ref-type="table"}).

###### Clinical, histologic, immunophenotypic and FISH features of discovery cohort patients

                                       Discovery cohort                                                                                                                              Validation cohort                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  ------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------
  **Mean age (range), years**          54.2 (28-76)                                                                                                                                  65.2 (44-76)                                                                               17.7 (3-40)                                                                                                                    66.3 (45-87)                                                                                                                                  59 (45-74)                                                                                 18.3 (5-43)
  **Male:female ratio**                10/3                                                                                                                                          5/2                                                                                        4/5                                                                                                                            7/3                                                                                                                                           5/2 (3NA)                                                                                  3/6
  **Oral**                             5                                                                                                                                             1                                                                                          1                                                                                                                              1                                                                                                                                             1                                                                                          1
  **Extra-Oral**                       8 (vulva, ileum, pleura, penis, skin)                                                                                                         6 (stomach, pleura, chest-wall, scrotum, vertebra)                                         8 (lymph-nodes, stomach, ileum, uterus, ovary)                                                                                 9 (Ileum, stomach, thyroid, chest-wall, lymph-node, colon)                                                                                    9 (iliac bone, chest-wall, lymph-node, vertebra)                                           8 (ileum, stomach, lymph-nodes)
  **Morphology**                       blastic *versus* more pronounced plasmacytic differentiation; necrosis, mitotic figures and apoptotic bodies with a "starry-sky" appearance   proliferation of mature plasma cells; 3 cases more blastic appearance, 1 case anaplastic   medium-sized cells, with monotonous and uniform appearance, squared-off cytoplasm, cohesive growth and starry-sky appearance   blastic *versus* more pronounced plasmacytic differentiation; necrosis, mitotic figures and apoptotic bodies with a "starry-sky" appearance   proliferation of mature plasma cells; 3 cases more blastic appearance, 1 case anaplastic   medium-sized cells, with monotonous and uniform appearance, squared-off cytoplasm, cohesive growth and starry-sky appearance
  **Immunophenotype**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  CD38                                 13                                                                                                                                            9                                                                                          9                                                                                                                              10                                                                                                                                            10                                                                                         9
  CD138                                13                                                                                                                                            9                                                                                          0                                                                                                                              10                                                                                                                                            10                                                                                         \-
  IRF4/MUM1                            13                                                                                                                                            \-                                                                                         0                                                                                                                              10                                                                                                                                            \-                                                                                         \-
  BCL2                                 13 (weak)                                                                                                                                     \-                                                                                         0                                                                                                                              10 (weak)                                                                                                                                     \-                                                                                         0
  BCL6                                 13 (weak)                                                                                                                                     0                                                                                          9                                                                                                                              10 (weak)                                                                                                                                     \-                                                                                         9
  CD10                                 13 (weak)                                                                                                                                     0                                                                                          9                                                                                                                              10 (weak)                                                                                                                                     \-                                                                                         9
  CD20                                 0                                                                                                                                             0                                                                                          9                                                                                                                              0                                                                                                                                             0                                                                                          9
  PAX5                                 0                                                                                                                                             0                                                                                          9                                                                                                                              0                                                                                                                                             0                                                                                          \-
  HHV8                                 0                                                                                                                                             \-                                                                                         \-                                                                                                                             2                                                                                                                                             \-                                                                                         \-
  ALK1                                 0                                                                                                                                             \-                                                                                         \-                                                                                                                             0                                                                                                                                             \-                                                                                         \-
  CD56                                 1                                                                                                                                             \-                                                                                         \-                                                                                                                             \-                                                                                                                                            \-                                                                                         \-
  MYC (20-50%)                         0                                                                                                                                             2                                                                                          0                                                                                                                              0                                                                                                                                             \-                                                                                         0
  MYC (\>50%)                          5                                                                                                                                             0                                                                                          0                                                                                                                              7                                                                                                                                             \-                                                                                         0
  MYC (\>80%)                          8                                                                                                                                             0                                                                                          9                                                                                                                              2                                                                                                                                             \-                                                                                         9
  ***MYC*** **translocation (FISH)**   8/13                                                                                                                                          2/7                                                                                        9/9                                                                                                                            9/10                                                                                                                                          2/10                                                                                       9/9
  **EBV infection**                    12/13                                                                                                                                         2/7                                                                                        5/9                                                                                                                            4/10                                                                                                                                          0/10                                                                                       6/9
  **Immune suppression**               7/13                                                                                                                                          NA                                                                                         NA                                                                                                                             2/10                                                                                                                                          NA                                                                                         NA

**PBL:** plasmablastic lymphoma; **EMPC:** extramedullary plasmacitoma; **BL:** Burkitt lymphoma; **IHC:** immunohistochemistry; **pos.:** positivity; **neg.:** negativity; **NA.:** not available.

###### Primers' sets used for qPCR analysis of EBV-encoded genes

  Assay                               Primers set
  ----------------------------------- ----------------------------------------------
  *EBNA1*                             5'- TAC AGG ACC TGG AAA TGG CC- 3'
  5'- TCT TTG AGG TCC ACT GCC G-3'    
  *EBNA2*                             5'-TAA CCA CCC AGC GCC AAT C-3'
  5'- GTA GGC ATG ATG GCG GCA G 5'    
  *EBNA3c*                            5'- CTG GCA AAA CTT GCT CCA- 3'
  5'- GTG CTT CTG CCT TAT CAG A- 3'   
  *BHRF1*                             5'-AGA AAC ACC TCT CCG CCT TT-3'
  5'- ATC CAC ATG TTC GGT GTG TG-3'   
  *LMP1*                              5'- CAG TCA GGC AAG CCT ATG A-3'
  5'- CTG GTT CCG GTG GAG ATG A-3'    
  *BMRF1*                             5'- CAACACCGCACTGGAGAG- 3'
  5'- GCCTGCTTCACTTTCTTGG- 3'         
  *LMP2A*                             5'- AGC TGT AAC TGT GGT TTC CAT GAC-3'
  5'- GCC CCC TGG CGA AGA G-3'        
  *BLLF1*                             5\'-ATCCAGTTGTATTCAAGGTAGG-3\'
  5\'-ACTCATTATCACACGAACGG-3\'        
  *BZLF1*                             5'- AAA TTT AAG AGA TCC TCG TGT AAAACA TC-3'
  5'- CGC CTC CTG TTG AAG CAG AT-3'   
  *HPRT*                              5'-AGC CAG ACT TTG TTG GAT TTG-3'
  5'-TTT ACT GGC GAT GTC AAT AAG-3'   

###### qPCR and immunohistochemical latency results on validation cohort

                 RT-qPCR   IHC/ISH          
  -------------- --------- --------- ------ ------
  **EBNA-1**     4         6         n.p.   n.p.
  **EBNA-2/3**   0         10        n.p.   n.p.
  **LMP-1**      0         10        0      10
  **LMP-2**      4         6         3      7
  **EBER**       \-        \-        4      6
  **ZEBRA**      3         7         4      6
  **EaR**        4         6         3      7
  **EaD**        4         6         3      7
  **gp350**      0         10        0      10

**ISH:** in situ hybridization; **n.:** number of cases; **n.p.:** not performed

Together, these data indicate a non-canonical EBV-latency pattern in PBL.

Plasmablastic lymphomas can be divided into two groups based on the miRNA profiling {#s2_2}
-----------------------------------------------------------------------------------

First, we sought to investigate the relation of PBL with BL and EMPC as far as miRNA expression was concerned. When an unsupervised approach was used, namely PCA, PBL appeared relatively heterogeneous and was not clearly distinct from BL and EMPC, indicating some degree of similarity with both of them. To better determine the possible relation with these two tumors, we developed a miRNA expression-based cell type classifier to establish whether single PBL cases could be related to either one (or none) of the two (BL or EMPC). We found that 7 out of 13 cases were significantly closer to EMPC, 5 out of 13 to BL, and 1 was not clearly classified (Figure [2A-B](#F2){ref-type="fig"}, Table [4](#T4){ref-type="table"}). By a supervised analysis, we identified 136 cellular miRNA differentially expressed in the two new subgroups (Figure [2C](#F2){ref-type="fig"}; Table [5a](#T5){ref-type="table"} and [5b](#T5){ref-type="table"}): 123 were up-regulated in "EMPC-related" PBLs, while 13 were up-regulated in "BL-related" ones. Among others, the expression level of hsa-mir-192-5p, hsa-mir-1304-3p, hsa-mir-148a-3p, hsa-miR-365-3p was studied by RT-qPCR as technical validation. We observed that these miRNA were up-regulated in the cases belonging to the EMPC-related cluster and down-regulated in the BL-related samples, confirming NGS results (Figure [2D](#F2){ref-type="fig"}). Interestingly, the two groups of PBLs tended to differ also for some clinical features. The patients BL-related were younger (mean age: 50.2 years), with a slight male predominance (M:F= 3:2), an extra-oral localization and a blastic appearance; the majority of them (4 out 5) were HIV-negative. The patients EMPC-related were older (mean age: 56.85 years), mainly male (M:F= 6:1), with an oral localization (4 out 7) and a more pronounced plasmacytic differentiation; the majority of them (4 out 7) were HIV-positive. Of note, 5/5 BL-related cases presented with *MYC* rearrangements at FISH, while only 2/7 EMPC presented with such feature (fisher exact test, p=0.03).

![Plasmablastic lymphomas include two molecular subgroups related to either EMPC or BL\
Principal component analysis of plasmablastic lymphoma (PBL), extramedullary plasmacytoma (EMPC) and Burkitt lymphoma (BL) cases indicated a basic relation between the three entities at miRNA level **A.**. A cell type classifier based on a support vector machine algorithm was generated to discriminate BL and EMPC based on the expression of differentially expressed miRNA. When the algorithm was applied to PBL, they were classified as either BL or EMPC indicating their heterogeneity reflecting the similarity to either one of the other two tumor types (BL and EMPC) **B.**. Grey zone represent value below significance (0.05). Supervised analysis (*t*-test) comparing BL-related *versus* EMPC-related PBLs identified a series of differentially expressed genes **C.**. In the matrix, the dendrogram was generated using a hierarchical clustering algorithm based on the average-linkage method. In the matrix, each column represents a sample and each row represents a gene. The colour scale bar shows the relative gene expression changes normalized by the standard deviation (0 is the mean expression level of a given gene). Differential expression of hsa-miR-192-5p, hsa-miR-1304-3p, hsa-miR-148a-3p and hsa-miR-365-3p in BL-related *versus* EMPC-related PBLs group **D.**-**G.** Values are expressed as mean ± standard deviation (ST). Statistical significance was determined with Student\'s unpaired *t*-test (*p* \< 0.005).](oncotarget-08-107356-g002){#F2}

###### Correlation between PBL and BL or EMPC

  Identifier     Cell type   Predicted   Confidence Measure
  -------------- ----------- ----------- --------------------
  H122 (raw)     PBL         BL          0.09583959
  V109 (raw)     PBL         BL          0.10874487
  s838 (raw)     PBL         BL          0.1592613
  s613 (raw)     PBL         BL          0.20450206
  s806 (raw)     PBL         BL          0.23559976
  s1805 (raw)    PBL         EMPC        0.27476195
  H276 (raw)     PBL         EMPC        0.45076987
  s1529 (raw)    PBL         EMPC        0.4700034
  s13725 (raw)   PBL         EMPC        0.47044697
  s11224 (raw)   PBL         EMPC        0.5045746
  s189 (raw)     PBL         BL          0.59934336
  H333 (raw)     PBL         EMPC        0.6791907
  V376 (raw)     PBL         EMPC        0.95444125

###### miRNA differentially expressed in the two PBL groups (BL-related *versus* EMPC-related)

  miRNA               p          Fold change   Regulation in BL-related group
  ------------------- ---------- ------------- --------------------------------
  hsa-let-7a-5p       0.028575   256           down
  hsa-let-7b-5p       0.006063   10809.406     down
  hsa-let-7d-3p       0.044231   2.6918004     down
  hsa-let-7d-5p       0.012786   3.482202      down
  hsa-let-7e-5p       0.028014   4.3297553     down
  hsa-let-7f-5p       0.018527   159.15468     down
  hsa-let-7g-5p       0.046021   13.387893     down
  hsa-miR-101-3p      0.002134   48.502926     down
  hsa-miR-103a-3p     0.004657   21.5344       down
  hsa-miR-103b        0.011111   18.74678      down
  hsa-miR-106b-3p     0.02385    4.594794      down
  hsa-miR-106b-5p     0.025859   13.125367     down
  hsa-miR-10b-5p      0.045394   1.17E+07      down
  hsa-miR-125a-5p     0.022511   40.58451      down
  hsa-miR-125b-1-3p   0.002118   2.6918004     down
  hsa-miR-126-3p      0.012516   128           down
  hsa-miR-126-5p      0.0226     159.15468     down
  hsa-miR-127-3p      0.030994   86.13763      down
  hsa-miR-128-3p      0.00253    8.659511      down
  hsa-miR-1304-3p     0.039182   5.0730634     down
  hsa-miR-130a-3p     0.015367   5.0730634     down
  hsa-miR-130b-3p     0.024846   5.278032      down
  hsa-miR-132-3p      0.003019   3.8446627     down
  hsa-miR-139-5p      0.037432   2.122426      down
  hsa-miR-140-3p      0.004751   436.9814      down
  hsa-miR-140-5p      0.038232   2.164878      down
  hsa-miR-143-3p      0.023024   40743.586     down
  hsa-miR-145-3p      0.034978   4.780439      down
  hsa-miR-145-5p      0.019368   26.250734     down
  hsa-miR-146a-5p     0.002346   111.43049     down
  hsa-miR-146b-5p     0.003099   1176.267      down
  hsa-miR-148a-3p     0.003072   1.38E+10      down
  hsa-miR-148b-3p     0.001742   13.387893     down
  hsa-miR-151a-3p     0.017852   49.47307      down
  hsa-miR-155-5p      0.042635   62.74499      down
  hsa-miR-15a-5p      0.01427    4.9735837     down
  hsa-miR-15b-5p      0.029421   3.0920668     down
  hsa-miR-16-5p       0.002014   5967.2734     down
  hsa-miR-181a-3p     0.00621    2.390219      down
  hsa-miR-181a-5p     0.003179   26353.643     down
  hsa-miR-181b-5p     0.028867   218.4907      down
  hsa-miR-181c-5p     0.024008   5.0730634     down
  hsa-miR-182-5p      0.041277   141.3235      down
  hsa-miR-183-5p      0.017472   34.638054     down
  hsa-miR-186-5p      0.006628   182.82076     down
  hsa-miR-191-5p      0.003595   6854.601      down
  hsa-miR-192-5p      0.003457   10.146127     down
  hsa-miR-193b-3p     0.003606   179.23567     down
  hsa-miR-195-5p      0.037465   3.3469734     down

###### miRNA differentially expressed in the two PBL groups (BL-related *versus* EMPC-related)

  miRNA             p          Fold change   Regulation in BL-related group
  ----------------- ---------- ------------- --------------------------------
  hsa-miR-196a-5p   0.033883   9.373392      down
  hsa-miR-197-3p    0.02192    13.387893     down
  hsa-miR-199a-3p   0.043553   8.489703      down
  hsa-miR-210-3p    0.020199   5.1745324     down
  hsa-miR-2110      0.020158   2             down
  hsa-miR-212-3p    0.037432   2.122426      down
  hsa-miR-21-3p     0.027591   25.73597      down
  hsa-miR-214-3p    0.016095   5.1745324     down
  hsa-miR-21-5p     0.016598   1.60E+09      down
  hsa-miR-221-3p    0.009039   194.0117      down
  hsa-miR-221-5p    0.019567   3.482202      down
  hsa-miR-222-3p    0.001477   120.616684    down
  hsa-miR-22-3p     0.021866   144.15012     down
  hsa-miR-23a-3p    0.008328   48.502926     down
  hsa-miR-23b-3p    0.03084    48.502926     down
  hsa-miR-24-3p     0.047314   13.655676     down
  hsa-miR-25-3p     4.42E-04   324.6761      down
  hsa-miR-26a-5p    0.006917   8693.463      down
  hsa-miR-26b-5p    8.58E-04   93.23874      down
  hsa-miR-27a-3p    0.011841   1176.267      down
  hsa-miR-27b-3p    0.011343   512           down
  hsa-miR-27b-5p    0.048211   2             down
  hsa-miR-28-3p     0.001606   50.4626       down
  hsa-miR-28-5p     7.68E-04   6.0628657     down
  hsa-miR-29b-3p    0.012198   5.6011167     down
  hsa-miR-29c-3p    0.004106   7.3907156     down
  hsa-miR-29c-5p    0.001043   3.482202      down
  hsa-miR-301a-3p   0.00456    4.504692      down
  hsa-miR-3074-5p   0.00282    5.3836007     down
  hsa-miR-30a-5p    0.028991   70.66175      down
  hsa-miR-30b-5p    0.006546   7.1037035     down
  hsa-miR-30c-5p    0.003975   15.686253     down
  hsa-miR-30d-5p    0.020276   86.13763      down
  hsa-miR-30e-3p    0.009217   5.6011167     down
  hsa-miR-30e-5p    0.012316   231.86519     down
  hsa-miR-3184-3p   0.036321   3.8446627     down
  hsa-miR-3184-5p   0.047828   29.562862     down
  hsa-miR-324-5p    0.007311   2.8565736     down
  hsa-miR-326       0.017578   2.6918004     down
  hsa-miR-328-3p    0.040136   3.6228948     down
  hsa-miR-340-5p    0.029992   2.6918004     down
  hsa-miR-345-5p    3.51E-05   5.3836007     down
  hsa-miR-34a-5p    0.025859   13.125367     down
  hsa-miR-3613-5p   0.017127   3.2169964     down
  hsa-miR-361-3p    0.018605   9.009385      down
  hsa-miR-3615      0.006715   6.562682      down
  hsa-miR-361-5p    0.011483   5.7131467     down
  hsa-miR-365a-3p   0.024084   2.3433483     down
  hsa-miR-374a-5p   0.001147   2.4867918     down
  hsa-miR-374b-5p   7.10E-04   3.1539128     down
  hsa-miR-378a-3p   0.010879   59.125725     down
  hsa-miR-378d      0.007875   3.1539128     down
  hsa-miR-381-3p    0.015433   2.122426      down
  hsa-miR-423-3p    0.01819    64            down
  hsa-miR-425-5p    0.025742   10.146127     down
  hsa-miR-4448      0.043389   18.01877      down
  hsa-miR-454-3p    0.008394   5.0730634     down
  hsa-miR-4633-5p   0.030738   49.47307      down
  hsa-miR-497-5p    0.008057   4.244852      down
  hsa-miR-500a-3p   0.01973    3.0920668     down
  hsa-miR-502-3p    0.015503   3.031433      down
  hsa-miR-574-3p    0.018238   3.9215622     down
  hsa-miR-615-3p    0.032965   3.1539128     down
  hsa-miR-625-3p    0.016429   7.390717      down
  hsa-miR-629-5p    0.012786   3.482202      down
  hsa-miR-652-3p    0.037863   7.843124      down
  hsa-miR-654-3p    0.042732   2.3433483     down
  hsa-miR-660-5p    0.023198   2.5365317     down
  hsa-miR-664a-3p   0.007032   2.4867918     down
  hsa-miR-6737-5p   0.028424   2.0400033     down
  hsa-miR-92b-3p    0.004056   1747.9257     down
  hsa-miR-93-5p     0.014503   56.829643     down
  hsa-miR-96-5p     0.027386   3.482202      down
  hsa-miR-98-5p     0.037122   3.4139185     down
  hsa-miR-3178      0.025964   66.58581      up
  hsa-miR-3648      0.010903   4.080006      up
  hsa-miR-4492      0.037656   91768.664     up
  hsa-miR-4497      0.029851   3859.7363     up
  hsa-miR-4508      0.039168   1108.4174     up
  hsa-miR-5787      0.01597    22492.303     up
  hsa-miR-6087      0.032981   14.207409     up
  hsa-miR-6126      0.001043   12.125731     up
  hsa-miR-663b      0.019219   5.6011167     up
  hsa-miR-6739-5p   1.33E-04   3.482202      up
  hsa-miR-6743-5p   0.029317   4.594794      up
  hsa-miR-7704      0.026789   62990.94      up
  hsa-miR-8072      0.034227   2.0808065     up

When we applied the cell classifier based on the expression of hsa-mir-192-5p, hsa-mir-1304-3p, hsa-mir-148a-3p, hsa-miR-365-3p to an independent set of 10 cases, we found that 3/9 cases were classified as EMPC-related and 6/9 as BL-related, one case not being evaluable for technical reasons (qPCR failure) ([Supplementary Figure 1](#SD1){ref-type="supplementary-material"}). Noteworthy, training and test set were comparable concerning HIV infection (6/13 vs 2/10, Fisher exact test, p=0.09)

Plasmablastic lymphomas and plasmacytomas have different miRNA profiles {#s2_3}
-----------------------------------------------------------------------

In order to unveil specific differences between the PBL and EMPC, we compared the two diseases in term of miRNA expression. When unsupervised approach was adopted, both principal component analysis (PCA) and hierarchical clustering (HC) failed to clearly separate the two entities (data not shown). Then, by supervised analysis, we identified 48 differentially expressed miRNA, including 38 EBV-encoded and 10 cellular miRNA which could clearly differentiate the two groups when PCA and HC methods were applied (Figure [3A-3B](#F3){ref-type="fig"}, [Supplementary Table 2](#SD3){ref-type="supplementary-material"}). Of note, a linear discriminant analysis indicated that as few as four miRNA (miR-665, miR-3613-5p, miR-1304-3p and miR-3609) could correctly discriminate the samples. Accordingly, based on the expression of such 4 miRNA, we generated a cell classifier and applied it to our series, being able to correctly classify all cases (overall accuracy 100%; Table [6](#T6){ref-type="table"}; Figure [3C](#F3){ref-type="fig"}). The expression of these four miRNA was also validated by RT-qPCR in the same panel of cases, confirming NGS results ([Supplementary Figure 2](#SD1){ref-type="supplementary-material"}). Furthermore, for the potential diagnostic implication, we studied their expression by qPCR in an independent validation cohort, consisting of 20 cases (10 PBL and 10 EMPC). When the cell classifier was applied, 9/10 EMPC and 10/10 PBL were correctly identified (95% overall accuracy; [Supplementary Figure 2](#SD1){ref-type="supplementary-material"}; Table [7](#T7){ref-type="table"}). All the three anaplastic EMPC included in the analysis were correctly classified.

![Plasmablastic lymphoma and extramedullary plasmacytoma are distinct based on the miRNA profile\
Principal component analysis of plasmablastic lymphoma (PBL) and extramedullary plasmacytoma (EMPC) cases **A.**. Supervised analysis (*T*-test) comparing PBL and EMPC cases identified a series of differentially expressed genes **B.**. In the matrix B, the dendrogram was generated using a hierarchical clustering algorithm based on the average-linkage method. In the matrix, each column represents a sample and each row represents a gene. The colour scale bar shows the relative gene expression changes normalized by the standard deviation (0 is the mean expression level of a given gene). A cell type classifier based on a support vector machine algorithm was generated to discriminate PBL and EMPC based on the expression of differentially expressed miRNA **C.**. Grey zone represent value below significance (0.05). Differential expression of hsa-miR-665, hsa-miR-3613-5p, hsa-miR-1304-3p and hsa-miR-3609 in PBL *versus* EMPC group **D.**. Values are expressed as mean ± standard deviation (ST). Statistical significance was determined with Student\'s unpaired *t*-test (*p* \< 0.005).](oncotarget-08-107356-g003){#F3}

###### Molecular diagnosis of PBL *versus* EMPC: diagnostic accuracy of the 4-miRNA based classifier in the discovery set

                                            Conventional histopathology   
  -------------------------- -------------- ----------------------------- ------------
                                            PBL                           EMPC
  **miRNA profiling**        *PBL*          13                            0
  *EMPC*                     0              7                             
                                                                          
                                            **Value**                     **95% CI**
  **Accuracy**               **SP**         100%                          100-100
  **ST**                     100%           100-100                       
  **PPV**                    100%           100-100                       
  **NPV**                    100%           100-100                       
  **LR+**                    10             1.56 to 64.20                 
  **LR-**                    NC             NC                            
  **Overall accuracy**       100% (20/20)                                 
  **Pre-test probability**   50%            28-72                         

###### Molecular diagnosis of PBL *versus* EMPC: diagnostic accuracy of the 4-miRNA based classifier in the validation set

                                           Conventional histopathology   
  -------------------------- ------------- ----------------------------- ------------
                                           PBL                           EMPC
  **miRNA profiling**        *PBL*         10                            1
  *EMPC*                     0             9                             
                                                                         
                                           **Value**                     **95% CI**
  **Accuracy**               **SP**        90%                           71-100
  **ST**                     100%          100-100                       
  **PPV**                    91%           74-100                        
  **NPV**                    100%          100-100                       
  **LR+**                    10            1.56 to 64.20                 
  **LR-**                    NC            NC                            
  **Overall accuracy**       95% (19/20)                                 
  **Pre-test probability**   50%           28-72                         

Plasmablastic lymphomas and Burkitt lymphomas have different miRNA profiles {#s2_4}
---------------------------------------------------------------------------

We then compared PBL to BL. By PCA the two diseases appeared relatively similar, without clear distinction (Figure [4A](#F4){ref-type="fig"}). By supervised analysis, we could identify a series of 42 differentially expressed miRNA (23 cellular and 19 EBV miRNA) (Figure [4B](#F4){ref-type="fig"}, [Supplementary Table 3](#SD4){ref-type="supplementary-material"}). As technical validation, some of them (hsa-miR-148-5p, hsa-miR-1273f, hsa-miR-4488, hsa-miR-494-3p; EBV-miR-BART10-3p, EBV-miR-BART18-3p and EBV-miR-BART19-5p) were also evaluated by qPCR, that again confirmed NGS data (Figure [4C](#F4){ref-type="fig"}). With the exception of miR-148a-5p, all cellular miRNA were up-regulated in PBL cases in respect to BL samples; a higher expression of all viral miRNA was detected in BL in comparison to PBL group.

![Plasmablastic lymphoma and Burkitt lymphoma are distinct based on the miRNA profile\
Principal component analysis of plasmablastic lymphoma (PBL) and Burkitt lymphoma (BL) cases **A.**. Supervised analysis (*t*-test) comparing PBL and BL cases identified a series of differentially expressed genes **B.**. In the matrix B, the dendrogram was generated using a hierarchical clustering algorithm based on the average-linkage method. In the matrix, each column represents a sample and each row represents a gene. The colour scale bar shows the relative gene expression changes normalized by the standard deviation (0 is the mean expression level of a given gene). Cellular miRNA (hsa-miR-1273f, hsa-miR-148a-5p, hsa-miR-4488, hsa-miR-494-3p) and EBV-viral miRNA (EBV-miR-Bart10-3p, EBV-miR-18-3p, EBV-miR-19-5p) expression in PBL *versus* BL cohort groups **C.**. Values are expressed as mean ± standard deviation (ST). Statistical significance was determined with Student\'s unpaired *t*-test (*p* \< 0.005).](oncotarget-08-107356-g004){#F4}

These findings were also confirmed in our validation cohort ([Supplementary Figure 3](#SD1){ref-type="supplementary-material"}).

Plasmablastic lymphomas differ in the miRNA profile based on HIV infection {#s2_5}
--------------------------------------------------------------------------

Since the association with HIV might affect PBL miRNA profiling, we directly compared HIV-positive *versus* HIV-negative cases. Unsupervised evaluation by PCA was already able to distinguish the two groups (Figure [5A](#F5){ref-type="fig"}). Further, the supervised analysis identified as many as 68 differentially expressed miRNA all of which were of cellular origin and were up-regulated in the HIV-positive group ([Supplementary Table 4](#SD5){ref-type="supplementary-material"}). By contrast, no EBV-encoded miRNA was differentially expressed. Based on the expression of such 68 miRNA, the cases were clearly distinct at HC (Figure [5B](#F5){ref-type="fig"}). None of the so far known HIV encoded miRNA emerged as significantly discriminating the two groups at NGS analysis. Therefore, in order to exclude possible underestimation of HIV-encoded miRNA contribution, we used a more sensitive qPCR approach to investigate this issue further. Although at low level, we found that both the tested HIV-encoded miRNA (HIV-miR-N-367 and HIV-miR-TAR-3p) were expressed in HIV cases but not in the negative ones (Figure [5C-5D](#F5){ref-type="fig"}).

![Plasmablastic lymphomas differ in their miRNA profile according to the presence of HIV\
Principal component analysis of HIV-positive and HIV-negative plasmablastic lymphomas (PBLs) indicated a rough distinction of the two groups based on miRNA expression **A.**. Supervised analysis (*T*-test) comparing HIV-positive *versus* HIV-negative PBLs identified a series of differentially expressed genes **B.**. In the matrix, the dendrogram was generated using a hierarchical clustering algorithm based on the average-linkage method. In the matrix, each column represents a sample and each row represents a gene. The colour scale bar shows the relative gene expression changes normalized by the standard deviation (0 is the mean expression level of a given gene). 5C. HIV-miR-367 expression in HIV positive and HIV negative PBL cases **C.**. HIV-miR-TAR-3p expression in HIV positive and HIV negative PBL cases **D.**.](oncotarget-08-107356-g005){#F5}

Key cellular signaling pathways and metabolic activities may be affected by deregulated cellular and viral miRNA {#s2_6}
----------------------------------------------------------------------------------------------------------------

To explore the potential involvement of the detected miRNA in PBL pathogenesis, we searched for genes targeted by the miRNA discriminating the molecular subtypes of PBL that were previously confirmed as direct targets biochemically. Among others, we found genes encoding for tumor suppressors (*PTEN, PBX2*) and lipid metabolism controller (*PPARGC1A, PLIN2*/adipophilin) whose expression levels were found to be regulated by BART-19-5p, and *FOXK2*, a gene involved in the control of viral and cellular promoter elements, regulated by hsa-miR148a-5p, has-miR-3609, has-miR-365.

The expression level of the encoded proteins was then checked by immunohistochemistry in 13 PBL cases. BL-related cases presented with significantly higher degree of expression of PTEN, PBX2, PPARGC1A, PLIN2/adipophilin and FOXK2 (Figure [6A-6E](#F6){ref-type="fig"} and) (p\<0.05).

![PTEN, PBX2, PPARGC1A, PLIN2/adipophilin, and FOXK2 protein expression in the two sub-groups of PBL\
PTEN, PBX2, PPARGC1A, PLIN2/adipophilin and FOXK2 showed lower level of expression in all the PBL cases that clustered closer to the EMPC cases than to the BL cases; one representative case for each sub-group is depicted. **A.**-**E.**, O.M.: 40x. PBL: plasmablastic lymphoma; EMPC: extramedullary plasmacytoma; BL: Burkitt lymphoma.](oncotarget-08-107356-g006){#F6}

We also investigated the potential pathobiological relevance of these genes by gene set enrichment analysis (GSEA). We found several gene sets significantly enriched; among others those associated to Kruppel-like factor 1 (*KLF1*), enhancer of zeste 2 polycomb repressive complex 2 subunit (*EZH2*) and *MYC* appeared of particular interest due to the high scores and consistent recurrence ([Supplementary Table 5](#SD6){ref-type="supplementary-material"}).

Novel miRNA discovery {#s2_7}
---------------------

We analyzed 13 PBL miRNA-seq libraries to identify candidate novel miRNA species that were deregulated in this tumor type. After sequence filtering, we enumerated 133 candidate novel miRNA, not identified in miRBase v21 ([Supplementary Table 6](#SD7){ref-type="supplementary-material"}). Differential expression analysis was carried out between PBL *versus* EMPC and PBL *versus* BL. We found 27 miRNA differentially expressed between PBL and BL, and 7 between PBL and EMPC ([Supplementary Tables 7](#SD8){ref-type="supplementary-material"}-[8](#SD9){ref-type="supplementary-material"}). Further, 17 miRNA discriminated the HIV positive cases from the HIV negative ones ([Supplementary Table 9](#SD10){ref-type="supplementary-material"}). Conversely, none of the putative novel miRNA were differentially expressed in PBLs according to their relation with EMPC or BL. Of note, one of these novel putative miRNA mapped on the HIV genome. However, these preliminary observations need appropriate validation.

DISCUSSION {#s3}
==========

The pathogenesis of PBL has not been clearly defined but most likely it involves deregulation of terminal B-cell differentiation and apoptosis, *via* the effect of *MYC* gene rearrangements and possibly EBV infection \[[@R3]\]. To better understand the viral program expressed in PBLs, we performed a complete assessment of EBV-encoded genes and proteins, demonstrating a non-canonical latency-associated program with the expression of latency II characterizing viral proteins along with sporadic lytic cycle reactivation. Nonetheless, the absence of *BLLF1*/gp350 expression in all the cases indicated an abortive lytic cycle in neoplastic cells. These results are consistent with previous findings, suggesting that EBV lytic reactivation may have pathogenic relevance in the context of both active and depressed immune response \[[@R6]\]. Intriguingly, we have recently demonstrated a non-canonical latency program with activation of the lytic cycle also in endemic BL cases, highlighting another overlap between PBL and BL \[[@R7]\].

The limited knowledge on PBL biology likely contributes to suboptimal management and poor prognosis of the patients. Therefore, in the present study we attempted to shed new light on the molecular bases of PBL. We studied for the first time the miRNA expression profile of PBL and compared it with those of BL and EMPC, chosen as the closest neoplastic counterparts considering morphological, immunophenotypic, genetic and epidemiological factors.

For the first time we observed that PBL include at least two molecular subgroups that presented with clinico-pathological peculiar features, including *MYC* rearrangements and HIV-association that appeared as main drivers of this sub-classification. On the other hand, this might be also due to a dissimilar histogenesis, genetic background and/or microenvironmental influences \[[@R5], [@R7], [@R8]\]. Interestingly, we found that the two PBL subgroups differed for the expression of proteins, the regulation of which might be sustained by the differentially expressed miRNA. These proteins turned out to be involved in relevant cellular processes including cell cycle and proliferation, signal transduction, apoptosis, viral replication, cell metabolism, epigenetic regulation of transcription (*via EZH2*) and differentiation. Of note, our findings unveiled another overlap between PBL and BL related to the metabolic reprogramming of the neoplastic cells \[[@R9]\]. In fact, both PBL and BL showed an activation of the lipid metabolism characterized by the expression of adipophilin, likely related to MYC activity as previously reported in the B-cell setting \[[@R10], [@R11]\].

Furthermore, we identified specific differences between PBL and both BL and EMPC as far as miRNA expression was concerned. Of note, based on the expression of as few as 4 miRNA, we could efficiently perform a molecular differential diagnosis between PBL and EMPC, even when anaplastic/plasmablastic EMPC were included. The latter, at present constitute real diagnostic challenges even for most experienced hematopathologists. Here, we demonstrated the efficiency of the molecular diagnostic tool in two independent cohorts of unselected cases, fulfilling the STARD criteria for molecular diagnostic. Phase 4 diagnostic accuracy studies are now warranted to prospectively evaluate the clinical utility of the test.

Finally, we observed that PBL molecular features are at least in part dependent on HIV status. Different mechanisms might be in place how HIV might contribute to PBL pathogenesis: duration and the degree of immunodeficiency, loss of immune control of oncogenic herpesviruses as EBV, chronic B-cell proliferation/exhaustion due to chronic antigenic stimulation, and/or factors unrelated to immune dysfunction, including a theoretically possible direct oncogenic effect. Actually, the involvement of HIV infection in PBL pathogenesis may explain the high frequency of this virus in PBL patients. In our analysis, HIV-positive and HIV-negative PBL cases differed in terms of cellular miRNA. This might be due in part to HIV itself by its own miRNA. However, only when qPCR was performed we could detect very low amounts of HIV-encoded miRNA in PBL cases. This likely reflected the inferior sensitivity of RNAseq analysis, especially when filters improving specificity and robustness are applied to RNAseq analysis. Indeed, the detection of viral miRNA is more likely consistent with the hypothesis that they were encoded in scattered T-cells, macrophages or dendritic cells rather than in the neoplastic clone. Nevertheless, their potential pathogenetic role in PBL cannot be excluded as miRNA are easily transferred through the tissues in the tumor microenvironment. Moreover, we identified by NGS a putative novel miRNA mapping on the HIV genome and highly expressed by PBL cells, the significance of which definitely need further analysis.

The major limitation of the study is probably the relatively low number of PBL cases analyzed (N=23). Nonetheless, it should be noted that all results have been validated in a cohort of cases independent from the discovery one, this making quite solid our assumptions \[[@R12]\].

In conclusion, the present study offers novel insights on PBL biology and pathogenesis that might be useful for the future management of this orphan disease in terms of classification, diagnosis and treatment. Particularly, an improved understanding of the complex interplay between genetic lesion and viral effects, as well as the multiple mechanisms regulating EBV reactivation might lead to the development of more specific therapies including miRNA-targeted therapies, MYC signaling pathways inhibitors, and combination of EBV lytic phase induction and anti-EBV drugs \[[@R13]\].

MATERIALS AND METHODS {#s4}
=====================

Cases selection, immunohistochemistry, fluorescent *in situ* hybridization (FISH) and EBER-in-situ hybridization {#s4_1}
----------------------------------------------------------------------------------------------------------------

For this study 23 PBL, 17 EMPC and 18 BL cases (9 endemic, 9 sporadic), collected at the Departments of Pathology of Aga Khan University Hospital, Nairobi (Kenya), Aga Khan Hospital, Kisumu (Kenya), Terni Hospital (Italy), and Siena University Hospital (Italy), were studied. Thirteen PBL, 7 EMPC and 9 BL (5 endemic) cases were used as discovery cohort for NGS-based miRNA profiling and EBV-latency assessment; 10 PBL, 10 EMPC and 10 BL cases were used as independent validation set of NGS analyses and were studied by qPCR and immunohistochemistry. The cases were reviewed by expert hemato-pathologists and diagnoses were confirmed by morphology on histological slides stained with haematoxylin and eosin (H&E) and Giemsa, and by immunophenotyping, according to the WHO \[[@R1], [@R14]\]. The following clinical data were collected: age, sex, disease location at presentation and an associated context of immunodeficiency.

Immunohistochemical studies were performed on representative paraffin sections from each case as previously reported \[[@R7], [@R15]\]. A large panel of antibodies (CD20, PAX-5, CD38, CD138, CD79a, CD10, BCL6, BCL2, MUM1, CD56, Igk, Igl) was applied to assess plasma cell differentiation. MYC protein expression and the proliferative index (by Ki-67) was evaluated. To rule out a diagnosis of ALK-positive large B-cell lymphoma or diffuse large B-cell lymphoma arising in multicentric Castlemann disease, immunohistochemical evaluation of ALK protein and HHV-8 was checked as well.

We studied the latency type of EBV by assessing the expression of some latent (EBNA-1, EBNA-2, EBNA-3, LMP-1, LMP-2A) and lytic proteins (EA-D, EA-R, BZLF1/ZEBRA, BLLF1/gp350) by immunohistochemistry. *In situ* hybridization for the non-coding EBERs was carried out in each sample as previously described \[[@R7]\]. A control slide, prepared from a paraffin-embedded tissue block containing metastatic nasopharyngeal carcinoma in a lymph node, accompanied each hybridization run.

In addition, the expression level of the proteins (adipophilin, PPARGC1A, FOXK2, PBX2, and PTEN) encoded by the genes found to be potentially targeted by the cellular and viral miRNA deregulated in the studied tumors was checked in the different primary tumors to highlight their positive or negative regulation by miRNA \[[@R16]\]. Differences in protein expression between cases were analyzed using the Chi-square test with p\<0.05 being statistical significant.

For all the stains, negative controls were obtained for each case by replacing the specific antibody with non-immune serum immunoglobulins at the same concentration as the primary antibody. Sections of reactive lymphoid tissue and of lymph node with infectious mononucleosis were used as positive control for plasma cell differentiation and EBV latency type and lytic phase.

FISH analysis for *MYC* rearrangements was performed using both dual-fusion probes and split-signal probes for IGH and IGL *loci* as well as an LSI IGH/*MYC* CEP 8 Tri-color dual-fusion probe (Vysis, Abbott Molecular IL, USA) \[[@R15]\].

All the clinical, morphological, immunophenotypical and cytogenetic features of the discovery cohort patients are summarized in Table [1](#T1){ref-type="table"}.

MicroRNA profiling {#s4_2}
------------------

Total RNA was extracted from formalyn-fixed paraffed-embedded (FFPE) sections of primary tumors and reactive lymph nodes using the FFPE miRNA Easy kit (Qiagen, CA), according to the manufacturer\'s instructions. Small RNA libraries were prepared from 1 μg of an high-quality RNA (RNA Integrity Number≥8) with the TruSeq Small RNA kit (Illumina). 1×36 sequencing was performed on the Illumina MiSeq platform. 36-bp length raw sequences were demultiplexed using the Illumina pipeline CASAVA v1.8. A quality check of the run experiment was performed by FastQC (<http://www.bioinformatics.babraham.ac.uk/projects/fastqc>). Low quality reads and adpater sequences were trimmed off using Trimmomatic \[[@R17]\]. The high quality reads, with a length of 17--36-bp were clipped and subsequently aligned to the latest mirBase release (v 21 July 2014) \[[@R18]\] by Novoalign (<http://www.novocraft.com>) MiRNA expression profiles were built by calculating the sum of read counts for each miRNA, according to the alignment criteria. Variance-stabilizing transformed count data were used to build an Euclidean distance matrix, followed by hierarchical clustering analysis to study the intra-samples correlations. miRNA differential expression analysis was performed using Bioconductor\'s package DESeq \[[@R19]\]. The obtained read counts for each identified miRNA were first normalized by scaling for library size factors in order to deal with variation among samples. The differential expression values were estimated using a negative binomial distribution model and local regression to estimate the relationship between the dispersion and the mean of each miRNA. Raw values were considered as statistically significant for p \<0.05. Following alignment and normalization, the data were analyzed using GeneSpring GX12 as previously described \[[@R20]--[@R25]\], by applying Pearson correlation (for unsupervised clustering) and two-tails Student t-test with p-value \<0.05 and fold change \>2 (for supervised clustering). The experimentally validated targets for the viral and cellular miRNA were searched in public databases. For the viral miRNA, we used VIRmiRNA (<http://crdd.osdd.net/servers/virmirna/>) \[[@R26]\]; for the cellular miRNA, miRWalk 2 (<http://zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk2/>) \[[@R27], [@R28]\]. Only proved direct interaction were then considered. Pathway analysis was performed by Gene Set Enrichment Analysis (GSEA) \[[@R29]\].

Reverse transcription-quantitative PCR (RT-qPCR) {#s4_3}
------------------------------------------------

The expression of EBV-encoded genes (*EBNA-1, EBNA-2, LMP-1, LMP-2, EBNA-3, BZLF-1 BMRF-1/Ea-D, BHRF-1/Ea-R,* BLLF1/*gp350*) characterizing the different latency programs, has been investigated by RT-qPCR using the QuantiTect SYBR Green PCR Kit (Qiagen, CA). The stably expressed housekeeping gene hypoxanthine-guanine phosphoribosyltransferase (HPRT) was used as an endogenous control and reference gene for relative quantification of each target gene. The relative expression is expressed as 2^ΔCt^, where ΔCt is defined as the difference in mean cycle thresholds of the gene of interest and HPRT.

The expression level of differentially expressed human (hsa-miR1304-3p, hsa-miR148a-3p, hsa-miR148a-5p, hsa-miR192-5p) and viral miRNA (EBV-miR-BART-10-5p, EBV-miR-BART-18-5p, EBV-miR-BART-19-3p), selected based on the score in differential analysis and the known biological relevance, was evaluated by using Taqman probes specific for each miRNA and for RNU6B (the endogenous control) (Apllied Viosystems, Applera, Italy). The relative expression of cellular miRNA was calculated using the 2^-∆∆ct^ formula; for viral miRNA the following formula was adopted: 2^-∆ct^ \[[@R30]\]. Primers used for qPCR analyses are detailed in Table [2](#T2){ref-type="table"}.

Diagnostic accuracy evaluation {#s4_4}
------------------------------

A diagnostic accuracy analysis was designed to test the ability of a newly developed molecular classifier (in particular of the 4-miRNAs based classifier) to discriminate PBL and EPCM. Calculations of sensitivity, specificity, positive predictive value, negative predictive value, positive and negative likelihood ratio, and odd ratio were made by CATmaker software (Centre for Evidence Based Medicine, Oxford University, <http://www.cebm.net>). The study was conducted according to the STARD guidelines for biomarker testing ([Supplementary Table 1](#SD2){ref-type="supplementary-material"}).

SUPPLEMENTARY MATERIALS FIGURES AND TABLES {#s5}
==========================================
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